MAPT and Alzheimer disease: Although it may be possible to incorporate this technique into clinical trials on a range of subjects with the whole spectrum of AD, the accuracy and potential clinical utility of PET-tau tracer in ABCD subjects require further research in clinically more representative populations (80).